Experience

Scarab Genomics

• United States
• Biotechnology
• 1 - 100 Employee

• Member Board of Directors

  • Mar 2023 - Present

  Madison, Wisconsin, United States Scarab Genomics has created Clean Genome® E. coli, a unique, patented set of bacterial hosts for reliable, high efficiency production of protein and nucleic acid biopharmaceuticals. Troublesome genetic elements, including IS elements and cryptic phages, and many nonessential genes, have been removed from the genome, resulting in more efficient and more reliable production. Clean Genome® E. coli is, unlike other hosts, capable of continuous production, which has been implemented as C-Flow™. A… Show more Scarab Genomics has created Clean Genome® E. coli, a unique, patented set of bacterial hosts for reliable, high efficiency production of protein and nucleic acid biopharmaceuticals. Troublesome genetic elements, including IS elements and cryptic phages, and many nonessential genes, have been removed from the genome, resulting in more efficient and more reliable production. Clean Genome® E. coli is, unlike other hosts, capable of continuous production, which has been implemented as C-Flow™. A typical 30-day C-Flow™ process yields 4.5 kg protein per month before purification at a mere 10-liter scale, dramatically reducing infrastructure requirements for substantial production volumes. Because production is continuous, conditions can be optimized on the fly, and because volumes are small, scale-up is rapid. Enabled by reduced genome strains, we sell research grade vaccine carrier proteins CRM197 and Protein D, and are developing continuous cGMP manufacturing of CRM197 for clinical needs. Scarab offers licensing options for research and for commercial production. Show less



Roswell

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President Assay Development

  • Mar 2021 - Dec 2021

  San Diego, California, United States



Serimmune Inc.

• United States
• Biotechnology
• 1 - 100 Employee

• Vice President, Product Development

  • Aug 2017 - Mar 2021

  Santa Barbara, California Area Serimmune uses diverse peptide libraries to characterize antibody repertoires, determining the antigen epitopes associated with many antibodies in parallel. Displayed peptides binding to antibodies in the repertoire are separated and their sequences are determined using NGS. Antigen epitopes specific to a sample, cohort, disease or phenotype are then discovered using statistical search algorithms and cloud computing. Serimmune's digital serology platform can be applied to Antigen… Show more Serimmune uses diverse peptide libraries to characterize antibody repertoires, determining the antigen epitopes associated with many antibodies in parallel. Displayed peptides binding to antibodies in the repertoire are separated and their sequences are determined using NGS. Antigen epitopes specific to a sample, cohort, disease or phenotype are then discovered using statistical search algorithms and cloud computing. Serimmune's digital serology platform can be applied to Antigen and antibody discovery Vaccine design and characterization Allergy and antigen identification Early disease detection Multiplex diagnostic panels Companion diagnostics Show less



SQI Diagnostics

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Vice President R&D/ Scientific Advisor

  • Oct 2010 - Mar 2021

  Toronto Ontario Lead R&D program for multiplexed immunoassays, developing fully automated planar protein microarrays that quantitate the isotype response to multiple antigens in a single well. Strategic focus on IVD assays for autoimmune disease and bioanalytics for drug development including immunogenicity (ADA). Key Responsibilities: • Provide scientific leadership and manage the product pipeline from… Show more Lead R&D program for multiplexed immunoassays, developing fully automated planar protein microarrays that quantitate the isotype response to multiple antigens in a single well. Strategic focus on IVD assays for autoimmune disease and bioanalytics for drug development including immunogenicity (ADA). Key Responsibilities: • Provide scientific leadership and manage the product pipeline from early phase feasibility, through reagent optimization and scale up to assay development, and verification/validation. • Interface with technology team to integrate assays with automated platform functions and analytical software. • Support Quality and Regulatory Systems: documentation and design records for ISO compliance and IVD filings • Represent SQI’s technology in meetings, collaborations and publications. Show less



BD

• United States
• Medical Equipment Manufacturing
• 700 & Above Employee

• Director, R&D, Reagent and Assay Development

  • Jan 2004 - Nov 2010

  Responsible for development of recombinant proteins, monoclonal antibodies and new florescent conjugates along with expanding the menu of assays for the BD Cytometric Bead Array platform Key Responsibilities: • Molecular Engineering Team: Design and development of peptides and recombinant proteins for use as immunogens and assay standards for internal, cross-site and external collaborators. • Hybridoma program: Including development of new antibodies for cell-signaling, immunology and… Show more Responsible for development of recombinant proteins, monoclonal antibodies and new florescent conjugates along with expanding the menu of assays for the BD Cytometric Bead Array platform Key Responsibilities: • Molecular Engineering Team: Design and development of peptides and recombinant proteins for use as immunogens and assay standards for internal, cross-site and external collaborators. • Hybridoma program: Including development of new antibodies for cell-signaling, immunology and stem cell research. Design and validation of model systems for identifying regents for specific cell staining and flow cytometry application testing. Implementation of continuous improvement to optimize screening processes. • Process Development: Scale up, purification and conjugation of antibodies for cellular analysis from both in-house and licensing programs. • New dye development: Cross site transfer and adoption of new fluorescent dyes to enable highly multiplexed flow cytometry • CBA program,: Sustaining a cross-site effort to bring new multiplexed research immuno-assays to market as part of a high value product line. The CBA assay uses capture antibodies immobilized on dyed beads combined with fluorescently labeled detectors to be analyzed by flow cytometry. Contributed to development of clinical bead based assays, and supported Sales and Marketing with training, technical presentations and hardware/software validation. Show less



Dyax

• Associate Director, Research and Technology

  • Oct 2002 - Dec 2003

  Established and managed a high throughput screening laboratory which utilizes a Dyax phage display library and automated systems to identify Fab reagents for commercialization by BD Biosciences Key Responsibilities: • Set up a new Dyax facility on-site at Pharmingen/Becton Dickinson,, recruited and trained an outstanding team of scientists, managed BD/Dyax collaboration. Delivered recombinant Fabs now in commercial assays • Developed processes to manage inter program handoffs… Show more Established and managed a high throughput screening laboratory which utilizes a Dyax phage display library and automated systems to identify Fab reagents for commercialization by BD Biosciences Key Responsibilities: • Set up a new Dyax facility on-site at Pharmingen/Becton Dickinson,, recruited and trained an outstanding team of scientists, managed BD/Dyax collaboration. Delivered recombinant Fabs now in commercial assays • Developed processes to manage inter program handoffs, tracking and applications feedback. Benchmarked cost/ target hit rates and lab capacity. Engineered measurable process improvements Show less



Celera Corporation

• United States
• Biotechnology Research
• 1 - 100 Employee

• Sr Manger Antibody Engineering

  • 2001 - 2002

  Establishing a pipeline to validate targets discovered through Celera’s proteomic platform and developing therapeutic antibodies in oncology Key Responsibilities: • Identification and development of technologies to reduce the time and cost of generating reagents for target validation, including approaches to immunogen and antibody production. • Set up and staffed a new lab with molecular biology and phage library capabilities. • Lead in evaluation of key technologies for… Show more Establishing a pipeline to validate targets discovered through Celera’s proteomic platform and developing therapeutic antibodies in oncology Key Responsibilities: • Identification and development of technologies to reduce the time and cost of generating reagents for target validation, including approaches to immunogen and antibody production. • Set up and staffed a new lab with molecular biology and phage library capabilities. • Lead in evaluation of key technologies for generating human antibodies and development of feasibility studies for therapeutic antibody partnership Show less



Motorola Life Sciences

• Team Leader - Protein Bioarrays

  • 1998 - 2001

  • Inception and development of a protein bioarray incorporating the existing Codelink platform where feasible. Optimized functional antibody immobilization on gel surfaces and demonstrated feasibility of a quantitative multi-analyte chip-based immuno-assay. Co-development of technical and business strategy for protein bio-arrays. Technology assessment and evaluation of partnership opportunities. . Recruiting and leading a small technical team to cultivate and extend our protein bioarray… Show more • Inception and development of a protein bioarray incorporating the existing Codelink platform where feasible. Optimized functional antibody immobilization on gel surfaces and demonstrated feasibility of a quantitative multi-analyte chip-based immuno-assay. Co-development of technical and business strategy for protein bio-arrays. Technology assessment and evaluation of partnership opportunities. . Recruiting and leading a small technical team to cultivate and extend our protein bioarray technology. • Development of an anti-cytokine antibody array capable of providing a multi-analyte snapshot of the cellular response to toxins and pathogens. Technology assessment; feasibility studies related to array surfaces, dispense technologies, signal amplification, and the utility of alternative affinity reagents. Early stage product development: shelf life and reproducibility studies, software and system optimization. • Directed applications for technology team developing a novel electrical detection platform including protein detection, pathogen detection, and a bacterial viability assay. • Technical consulting and application design for Microfluidics program Show less



Boehringer Mannheim

• Scientist - Antibody Engineering

  • 1993 - 1998

  • Design, construction and bacterial expression of gene-level immunoconjugates to be used in diagnostic homogeneous immunoassays. • Training in the laboratory of Jim Marks at U.C.S.F., constructing and screening a phage display library of single chain antibodies derived from immunized mouse spleen. • Utilized phage display to select hormone specific antibodies and to select high affinity Fabs following directed CDR mutagenesis. • Screening of large naive human phage-display libraries… Show more • Design, construction and bacterial expression of gene-level immunoconjugates to be used in diagnostic homogeneous immunoassays. • Training in the laboratory of Jim Marks at U.C.S.F., constructing and screening a phage display library of single chain antibodies derived from immunized mouse spleen. • Utilized phage display to select hormone specific antibodies and to select high affinity Fabs following directed CDR mutagenesis. • Screening of large naive human phage-display libraries for antibody specificities of use in diagnostic assays. • Improving recombinant antibody specificity, affinity, expression levels and stability. • Collaboration with Dr. Greg Winter at the MRC in Cambridge devising and carrying-out protocols for the selection of conformation - specific antibodies. • Led team responsible for use of phage - displayed single-chain antibodies in identification of cell-surface proteins for rare cell enrichment. Show less



Laboratory of Tumor Immunology and Biology NCI/NIH,

• Post Doc/Staff Fellow

  • 1991 - 1993

  Working in the laboratory of S. Kashmiri, directed by Jeff Schlom. Responsibilities and Accomplishments • Cloning and modifying immunoglobulin genes directed against human tumor-associated antigens. • Construction, expression and purification of novel antibody derivatives for use in both diagnostic and therapeutic applications in the management of a range of human carcinomas. • Significantly improved the soluble expression of an anti tumor scFV in E.coli